A research group at the University of Turku, Finland, has discovered a completely new mechanism that cells use to circulate integrins on the cell surfac.
A research group at the University of Turku, Finland, has discovered a completely new mechanism that cells use to circulate integrins on the cell surface.
E-Mail
IMAGE: SORLA removal sensitizes metastatic breast cancer cells to HER2 targeting therapy. Aggressive metastatic breast cancer cells growing in the brains of fish embryos. The tumors are resistant to anti-HER2 therapy. view more
Credit: Ilkka Paatero from Turku Bioscience
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitized anti-HER2 resistant breast cancer brain metastasis to targeted therapy.